Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03534804
Title Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Utah
Indications

invasive bladder transitional cell carcinoma

transitional cell carcinoma

Therapies

Cabozantinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.